Proposed U.S. tariffs on generic drugs could push medicine prices higher for American patients, according to Erez Israeli, the chief executive of Indian drugmaker Dr. Reddy's. His warning points to the risk that a policy aimed at imports could make low-cost treatments less affordable in the U.S.
Dr. Reddy's is a major pharmaceutical company from India, a country that plays an important role in supplying generic medicines. If added tariffs raise the cost of bringing those products into the U.S., companies may face higher expenses that are then reflected in the prices paid by buyers and patients.
The concern is especially significant because generic drugs are widely used as lower-cost alternatives to brand-name medicines. Any increase in their price could affect patients who rely on affordable prescriptions, while also putting pressure on healthcare budgets and the broader supply chain.
Israeli's comments add to the debate over how trade measures can affect essential goods. While tariffs are often discussed in terms of industry and manufacturing, the warning from Dr. Reddy's highlights that changes in trade policy can also have direct consequences for everyday healthcare costs in the United States.
